Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ACTU Actuate Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: ACTU
Price (delayed)
$9.29
Market cap
$182.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.85
Enterprise value
$178.38M
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We
Highlights
ACTU's debt has shrunk by 100% YoY
Actuate Therapeutics's equity has soared by 95% YoY
Actuate Therapeutics's quick ratio has soared by 200% YoY but it has plunged by 57% from the previous quarter
The EPS has surged by 79% year-on-year but it has declined by 18% since the previous quarter
Key stats
What are the main financial stats of ACTU
Market
Valuations
Earnings
Shares outstanding
19.62M
Market cap
$182.27M
Enterprise value
$178.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$23.75M
Net income
-$25.31M
EBIT
-$25.29M
EBITDA
-$25.29M
Free cash flow
-$21.21M
Per share
Balance sheet
Liquidity
EPS
-$3.85
EPS diluted
-$3.85
Free cash flow per share
-$1.09
Book value per share
-$0.26
Revenue per share
$0
TBVPS
$0.23
Total assets
$4.48M
Total liabilities
$9.57M
Debt
$0
Equity
-$5.09M
Working capital
-$4.91M
Debt to equity
0
Current ratio
0.46
Quick ratio
0.42
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-339.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACTU stock price
How has the Actuate Therapeutics stock price performed over time
Intraday
2.2%
1 week
-21.93%
1 month
0.87%
1 year
N/A
YTD
16.71%
QTD
37.22%
Financial performance
How have Actuate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.75M
Net income
-$25.31M
Gross margin
N/A
Net margin
N/A
Actuate Therapeutics's operating income has increased by 13% YoY and by 6% from the previous quarter
ACTU's net income is up by 9% YoY and by 7% from the previous quarter
Price vs fundamentals
How does ACTU's price correlate with its fundamentals
Growth
What is Actuate Therapeutics's growth rate over time
Valuation
What is Actuate Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 79% year-on-year but it has declined by 18% since the previous quarter
Actuate Therapeutics's equity has soared by 95% YoY
Efficiency
How efficient is Actuate Therapeutics business performance
Actuate Therapeutics's ROA has soared by 67% YoY and by 13% from the previous quarter
Dividends
What is ACTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACTU.
Financial health
How did Actuate Therapeutics financials performed over time
Actuate Therapeutics's total assets is 53% lower than its total liabilities
Actuate Therapeutics's quick ratio has soared by 200% YoY but it has plunged by 57% from the previous quarter
Actuate Therapeutics's total assets has surged by 66% YoY but it has shrunk by 52% QoQ
ACTU's debt is 100% higher than its equity
ACTU's debt has shrunk by 100% YoY
ACTU's debt to equity has soared by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.